Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma

NCT00478426 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00478426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00478426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
February 12, 2019
Enrollment
34 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, recurrent uterine corpus carcinoma, stage iva uterine corpus cancer ajcc v7, stage ivb uterine corpus cancer ajcc v7, uterine carcinosarcoma, uterine corpus carcinosarcoma